{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:40:40Z","timestamp":1790214040521,"version":"4.1.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality. However, the efficacy and safety of ketamine in transitional age youth (TAY; age 18\u201325) populations remains understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this retrospective analysis, TAY patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200952) receiving ketamine for TRD were matched for sex, primary diagnosis, baseline depression severity, and treatment resistance with a general adult (GA) sample (age 30\u201360). Patients received four ketamine infusions over 2\u2009weeks (0.5\u20130.75\u2009mg\/kg over 40\u2009min). The primary outcome was the change in Quick Inventory of Depressive Symptomatology Self-Report 16-item (QIDS-SR16) over time. Secondary outcomes were changes in QIDS-SR16 suicidal ideation (SI) item, anxiety (Generalized Anxiety Disorder 7-item (GAD-7)), and adverse effects (ClinicalTrials.gov: NCT04209296).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A significant main effect of infusions on reduction of total QIDS-SR16 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), QIDS-SR16 SI (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and GAD-7 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) scores was observed in the TAY group with moderate effect sizes, indicative of clinically significant improvements in depression, anxiety, and suicidality. There were no significant differences between TAY and GA groups on these measures over time, suggesting comparable improvements in both groups. Safety and tolerability outcomes were comparable between groups with only mild, transient adverse effects observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ketamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811231171531","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T01:48:34Z","timestamp":1684288114000},"page":"775-783","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-5854","authenticated-orcid":false,"given":"Noah","family":"Chisamore","sequence":"first","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-9677","authenticated-orcid":false,"given":"Kevork","family":"Danayan","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-5612","authenticated-orcid":false,"given":"Nelson B","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D","family":"Di Vincenzo","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakila","family":"Meshkat","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Doyle","sequence":"additional","affiliation":[{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Mansur","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Phan","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-6061","authenticated-orcid":false,"given":"Farhan","family":"Fancy","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniqa","family":"Tabassum","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kratiuk","sequence":"additional","affiliation":[{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arekapudi","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S","family":"McIntyre","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-2191","authenticated-orcid":false,"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[{"name":"Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada"},{"name":"Brain and Cognition Discovery Foundation, Toronto, ON, Canada"},{"name":"Canadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2022.04.037"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2019.02.008"},{"key":"e_1_3_2_4_1","unstructured":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia predictors of metabolic dysregulation and association with psychopathology: a systematic review and network meta-analysis \u2013 The Lancet Psychiatry (n.d.). Available at: https:\/\/www.thelancet.com\/journals\/lanpsy\/article\/PIIS2215-0366(19)30416-X\/fulltext (accessed 23 September 2022)."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.09.002"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.02.058"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20010018"},{"key":"e_1_3_2_8_1","unstructured":"Frontiers | Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies (n.d.). Available at: https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.880496\/full (accessed 23 September 2022)."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000438185.81983.8b"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2009.05.016"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-020-01542-3"},{"key":"e_1_3_2_12_1","first-page":"171","article-title":"Metabolic consequences of second-generation antipsychotics in youth: Appropriate monitoring and clinical management","volume":"5","author":"Krill RA","year":"2014","unstructured":"Krill RA, Kumra S (2014) Metabolic consequences of second-generation antipsychotics in youth: Appropriate monitoring and clinical management. Adolesc Health Med Ther 5: 171\u2013182.","journal-title":"Adolesc Health Med Ther"},{"key":"e_1_3_2_13_1","doi-asserted-by":"crossref","unstructured":"Li K Zhou G Xiao Y et al. (2022) Risk of suicidal behaviors and antidepressant exposure among children and adolescents: A meta-analysis of observational studies. Front Psychiatry 13: 880496. Available at: https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.880496 (accessed 10 February 2023).","DOI":"10.3389\/fpsyt.2022.880496"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.623681"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2020.12.032"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015911795017155"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-62113-1_1"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.10.043"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12941"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.05.088"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.06.050"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-017-0855-x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00154-1"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchemneu.2018.12.002"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-021-05939-z"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18070834"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1776699"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.12.119"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852920002187"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.07.089"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X12666140619204251"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16010037"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371005500303"},{"key":"e_1_3_2_37_1","first-page":"23","article-title":"When at first you don\u2019t succeed: Sequential strategies for antidepressant nonresponders","volume":"58","author":"Thase ME","year":"1997","unstructured":"Thase ME, Rush AJ (1997) When at first you don\u2019t succeed: Sequential strategies for antidepressant nonresponders. J Clinical Psychiatry 58: 23\u201329.","journal-title":"J Clinical Psychiatry"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12284"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-62113-1_5"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17040472"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13699"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231171531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811231171531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811231171531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:23Z","timestamp":1777507883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811231171531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1177\/02698811231171531"],"URL":"https:\/\/doi.org\/10.1177\/02698811231171531","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}